Strong association between lung cancer and the AXIN2 polymorphism

Molecular Medicine Reports

Volumn 2, Issue 6, 2009, Pages 1029-1035

  Gunes, Emine Gulsen ^a   Pinarbasi, Ergun ^a   Pinarbasi, Hatice ^a   Silig, Yavuz ^a  

^a CUMHURIYET UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

AXIN2; Cancer predisposition; Lung cancer; Polymorphism; Turkish population

Indexed keywords

AXIS INHIBITION PROTEIN 1; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; EXON; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HISTOLOGY; HUMAN; INTRON; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION GENETICS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SEX RATIO; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; TURKEY (REPUBLIC);

EID: 73649092773     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000210     Document Type: Article

References (36)

1. Ginsberg RJ, Vokes EE and Raben A: Cancer of the lung. In: Cancer: Principles and Practice of Oncology. DeVita VT Jr, Hellman S and Rosenberg SA (eds). 5th edition. Lippincott-Raven, Philadelphia, pp858-865, 1997.
2. Marby M, Nelkin BD and Baylin SB: Lung cancer. In: The Genetic Basis of Human Cancer. Vogelstein B and Kinzler KW (eds). 2nd edition. McGraw-Hill, New York, pp671-679, 1998.
3. Khuder SA: Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer 31: 139-148, 2001.
4. Sekido Y, Fong KM and Minna JD: Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta 1378: 21-59, 1998.
5. Salgia R and Skarin AT: Molecular abnormalities in lung cancer. J Clin Oncol 16: 1207-1217, 1998.
6. Reissmann PT, Koga H, Figlin RA, Holmes EC and Slamon DJ: Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small cell lung cancer. Lung Cancer Study Group. J Cancer Res Clin Oncol 125: 61-70, 1999.
7. Pinarbasi H, Silig Y, Cetinkaya O, Seyfikli Z and Pinarbasi E: Strong association between the GSTM1-null genotype and lung cancer in a Turkish population. Cancer Genet Cytogenet 146: 125-129, 2003.
8. Bartsch H, Nair U, Risch A, Rojas M, Wikman H and Alexandrov K: Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 9: 3-28, 2000.
9. Schwartz AG, Prysak GM, Bock CH and Cote ML: The molecular epidemiology of lung cancer. Carcinogenesis 28: 507-518, 2007.
10. Kohno T and Yokota J: How many tumor suppressor genes are involved in human lung carcinogenesis? Carcinogenesis 20: 1403-1410, 1999.
11. Ohta M, Inoue H, Cotticelli MG, et al: The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint is abnormal in digestive tract cancers. Cell 84: 587-597, 1996.
12. Sard L, Accornero P, Tornielli S, et al: The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci USA 96: 8489-8492, 1999.
13. Kikuchi A: Modulation of Wnt signaling by axin and axil. Cytokine Growth Factor Rev 10: 255-265, 1999.
14. Hughes TA and Brady HJM: Cross-talk between pRb/E2F and Wnt/b-catenin pathways: E2F1 induces AXIN2 leading to repression of Wnt signalling and to increased cell death. Exp Cell Res 303: 32-46, 2005.
15. Phelan CM, Borg A, Cuny M, et al: Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters. Cancer Res 58: 1004-1012, 1998.
16. Plummer SJ, Paris MJ, Myles J, Tubbs R, Crowe J and Casey G: Four regions of allelic imbalance on 17q12-qter associated with high-grade breast tumors. Genes Chromosomes Cancer 20: 354-362, 1997.
17. Barlund M, Tirkkonen M, Forozan F, Tanner MM, Kallioniemi O and Kallioniemi A: Increased copy number at 17q22-q24 by CGH in breast cancer is due to high-level amplification of two separate regions. Genes Chromosomes Cancer 20: 372-376, 1997.
18. Taniguchi K, Roberts LR, Aderca IN, et al: Mutational spectrum of beta-catenin, AXIN1 and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 21: 4863-4871, 2002.
19. Wu R, Zhai Y, Fearon ER and Cho KR: Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 61: 8247-8255, 2001.
20. Liu W, Dong X, Mai M, et al: Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat Genet 26: 146-147, 2000.
21. Yokota N, Mainprize TG, Taylor MD, et al: Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization. Oncogene 23: 3444-3453, 2004.
22. Kanzaki H, Ouchida M, Hanafusa H, et al: Single nucleotide polymorphism of the AXIN2 gene is preferentially associated with human lung cancer risk in a Japanese population. Int J Mol Med 18: 279-284, 2006.
23. Wang X, Goode EL, Fredericksen ZS, et al: Association of genetic variation in genes implicated in the beta-catenin destruction complex with risk of breast cancer. Cancer Epidemiol Biomarkers Prev 17: 2101-2108, 2008.
24. Mostowska A, Biedziak B and Jagodzinski PP: Axis inhibition protein 2 (AXIN2) polymorphisms may be a risk factor for selective tooth agenesis. J Hum Genet 51: 262-266, 2006.
25. Risch A and Plass C: Lung cancer epigenetics and genetics. Int J Cancer 123: 1-7, 2008.
26. Yokobori T, Mimori K, Iwatsuki M, et al: p53-altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res 69: 3788-3794, 2009.
27. Miyaki M, Yamaguchi T, Iijima T, Takahashi K, Matsumoto H and Mori T: Somatic mutations of the CDC4 (FBXW7) gene in hereditary colorectal tumors. Oncology 76: 430-434, 2009.
28. Liu JN, Zhang XM, Guo YL, Sun T, Lin DX and Wen T: Genetic polymorphism in MDM2 is associated with susceptibility to colorectal cancer in a Chinese population. Zhonghua Zhong Liu Za Zhi 30: 335-338, 2008.
29. Ding L, Getz G, Wheeler DA, et al: Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075, 2008.
30. Shinmura K, Suzuki M, Yamada H, et al: Characterization of adenocarcinoma of the lung in a familial adenomatous polyposis patient. Pathol Int 58: 706-712, 2008.
31. Mechanic LE, Marrogi AJ, Welsh JA, et al: Polymorphisms in XPD and TP53 and mutation in human lung cancer. Carcinogenesis 26: 597-604, 2005.
32. Akiyama T: Wnt/beta-catenin signaling. Cytokine Growth Factor Rev 11: 273-282, 2000.
33. Bienz M and Clevers H: Linking colorectal cancer to Wnt signaling. Cell 103: 311-320, 2000.
34. Salahshor S and Woodgett JR: The links between axin and carcinogenesis. J Clin Pathol 58: 225-236, 2005.
35. Hart MJ, De los Santos R, Albert IN, Rubinfeld B and Polakis P: Down-regulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol 8: 573-581, 1998.
36. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E and Polakis P: Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275: 1790-1792, 1997.